REG - Haleon PLC GSK PLC - Holding(s) in Company

GSKAnnouncement

10/10/2023 11:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231010:nRSJ6392Pa&default-theme=true

RNS Number : 6392P  Haleon PLC  10 October 2023

10 October 2023

HALEON PLC

("Haleon" or "the Company") 

 

TR-1: Standard form for notification of major holdings

 

 

1. Issuer Details

ISIN

GB00BMX86B70

Issuer Name

HALEON PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An acquisition or disposal of voting rights

3. Details of person subject to the notification obligation

Name

GSK plc

City of registered office (if applicable)

BRENTFORD

Country of registered office (if applicable)

United Kingdom

 Name              City of registered office  Country of registered office
 GSK GP 1 Limited  Edinburgh                  Scotland
 GSK LP Limited    London                     England

4. Details of the shareholder

 Name                      City of registered office  Country of registered office
 Vidacos Nominees Limited  London                     England

5. Date on which the threshold was crossed or reached

06-Oct-2023

6. Date on which Issuer notified

09-Oct-2023

7. Total positions of person(s) subject to the notification obligation

                                                                            % of voting rights attached to shares (total of 8.A)  % of voting rights through financial instruments (total of 8.B 1 + 8.B 2)  Total of both in % (8.A + 8.B)  Total number of voting rights held in issuer
 Resulting situation on the date on which threshold was crossed or reached  7.420000                                              0.000000                                                                   7.420000                        685320110
 Position of previous notification (if applicable)                          10.350000                                             0.000000                                                                   10.350000

8. Notified details of the resulting situation on the date on which the
threshold was crossed or reached

8A. Voting rights attached to shares

 Class/Type of shares ISIN code(if possible)  Number of direct voting rights (DTR5.1)  Number of indirect voting rights (DTR5.2.1)  % of direct voting rights (DTR5.1)  % of indirect voting rights (DTR5.2.1)
 GB00BMX86B70                                 0                                        685320110                                    0.000000                            7.420000
 Sub Total 8.A                                685320110                                                                             7.420000%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

 Type of financial instrument  Expiration date  Exercise/conversion period  Number of voting rights that may be acquired if the instrument is  % of voting rights
                                                                            exercised/converted

 Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to
(DTR5.3.1R.(1) (b))

 Type of financial instrument  Expiration date  Exercise/conversion period  Physical or cash settlement  Number of voting rights  % of voting rights

 Sub Total 8.B2

9. Information in relation to the person subject to the notification
obligation

2. Full chain of controlled undertakings through which the voting rights
and/or the financial instruments are effectively held starting with the
ultimate controlling natural person or legal entities (please add additional
rows as necessary)

 Ultimate controlling person  Name of controlled undertaking                      % of voting rights if it equals or is higher than the notifiable threshold  % of voting rights through financial instruments if it equals or is higher  Total of both if it equals or is higher than the notifiable threshold
                                                                                                                                                              than the notifiable threshold
 GSK plc (Chain 1)                                                                2.850000                                                                                                                                                2.850000%
 GSK plc (Chain 1)            GlaxoSmithKline Holdings Limited (Chain 1)          2.850000                                                                                                                                                2.850000%
 GSK plc (Chain 1)            GlaxoSmithKline Finance plc (Chain 1)               2.850000                                                                                                                                                2.850000%
 GSK plc (Chain 1)            Glaxo Group Limited (Chain 1)                       2.850000                                                                                                                                                2.850000%
 GSK plc (Chain 2)                                                                4.580000                                                                                                                                                4.580000%
 GSK plc (Chain 2)            GSK LP Limited (Chain 2)                            4.580000                                                                                                                                                4.580000%
 GSK plc (Chain 2)            GSK GP 1 Limited (Chain 2)                          4.580000                                                                                                                                                4.580000%
 GSK plc (Chain 2)            GSK (No. 1) Scottish Limited Partnership (Chain 2)  4.580000                                                                                                                                                4.580000%

10. In case of proxy voting

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

11. Additional Information

GSK plc is making this notification on behalf of itself and on behalf of GSK
LP Limited and GSK GP 1 Limited.

This notification relates to the sale by GSK (No.1) Scottish Limited
Partnership, GSK (No.2) Scottish Limited Partnership and GSK (No.3) Scottish
Limited Partnership (entities that are indirectly wholly-owned by GSK plc) of
(in the case of GSK (No.1) Scottish Limited Partnership) a portion of its
interest and (in the case of GSK (No.2) Scottish Limited Partnership and GSK
(No.3) Scottish Limited Partnership) all of their respective interests in
Haleon plc.

GSK GP 1 Limited is the sole general partner of GSK (No.1) Scottish Limited
Partnership and GSK (No.2) Scottish Limited Partnership. GSK LP Limited is the
sole limited partner of GSK (No.1) Scottish Limited Partnership, GSK (No.2)
Scottish Limited Partnership and GSK (No.3) Scottish Limited Partnership.

Glaxo Group Limited and GSK (No.1) Scottish Limited Partnership hold their
shares in Haleon plc via a custodian, Vidacos Nominees Limited, which holds
the legal title to those shares on their behalf pursuant to a custody
arrangement.

12. Date of Completion

09-Oct-2023

13. Place Of Completion

London, England

 

Amanda Mellor, Company Secretary

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  HOLUROKROKURARA